1. Home
  2. XRAY vs COAG Comparison

XRAY vs COAG Comparison

Compare XRAY & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DENTSPLY SIRONA Inc.

XRAY

DENTSPLY SIRONA Inc.

N/A

Current Price

$8.74

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

COAG

Hemab Therapeutics Holdings Inc. Common Stock

N/A

Current Price

$31.06

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XRAY
COAG
Founded
1899
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.9B
IPO Year
2009
2026

Fundamental Metrics

Financial Performance
Metric
XRAY
COAG
Price
$8.74
$31.06
Analyst Decision
Hold
Strong Buy
Analyst Count
17
5
Target Price
$13.73
★ $61.20
AVG Volume (30 Days)
★ 4.1M
355.5K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 1.81%
N/A
EPS Growth
★ 33.04
N/A
EPS
★ 0.14
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.47
N/A
P/E Ratio
$64.57
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.90
$27.47
52 Week High
$14.73
$55.42

Technical Indicators

Market Signals
Indicator
XRAY
COAG
Relative Strength Index (RSI) 28.67 21.88
Support Level N/A $29.54
Resistance Level $10.66 $38.87
Average True Range (ATR) 0.36 2.57
MACD -0.05 -0.79
Stochastic Oscillator 5.69 1.10

Price Performance

Historical Comparison
XRAY
COAG

About XRAY DENTSPLY SIRONA Inc.

Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantology. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: